147P Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020

Autor: Dorbes, G. Gueguen, Loukili, N., Petain, A., Labbe, J., Boute, N., Akla, B., Broussas, M., Ferre, P., Hofmann, F.

Publikováno v: In Immuno-Oncology and Technology December 2023 20 Supplement

Data from Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma

Autor: Bruno Gomes, Nicolas Guilbaud, Pierre Ferré, Xavier Thuru, Laurent Nguyen, Thierry Marchal, Stéphane Couffin, Viviane Brel, Aurélie Pétain, Emmanuel Bouchaert, Ingrid Bemelmans, Zacharie Segaoula, François Serres, Dominique Tierny

Purpose: F14512 is a new topoisomerase II inhibitor containing a spermine moiety that facilitates selective uptake by tumor cells and increases topoisomerase II poisoning. F14512 is currently in a phase I/II clinical trial in patients with acute myel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a7a56b63ce7133a44dd0c33f0c33168
https://doi.org/10.1158/1078-0432.c.6524640.v1

Chimio-embolisation lipiodolée versus microsphères dans le traitement du carcinome hépato-cellulaire : étude sur explants

Autor: Pétain, Blandine

Publikováno v: Sciences du Vivant [q-bio]. 2021

Introduction : le cancer du foie, représenté à 90% par le CHC, est la 4e cause de mortalité par cancer dans le monde. La transplantation hépatique est le traitement idéal, permettant de traiter simultanément la tumeur et la pathologie hépatiq

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6cd1a5aa74490cbecc28ad91e9613c76
https://dumas.ccsd.cnrs.fr/dumas-03270865

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer

Autor: Marie-Paule Sablin, Christophe Le Tourneau, Nicolas Guilbaud, Carlos Gomez-Roca, Jean-Pierre Delord, Mariya Pavlyuk, Andrea Varga, Aurélie Pétain, Alexandra Leary

Publikováno v: Investigational New Drugs

Summary Purpose To determine the maximum tolerated dose (MTD) of F14512, a topoisomerase II inhibitor designed to target cancer cells through the polyamine transport system, (three-hour daily infusion given for 3 consecutive days every 3 weeks) in pl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::202e65862d2b7c8e01527b00baefb0f9
https://doi.org/10.1007/s10637-018-0688-4

Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma

Autor: Quentin Pascal, Nicolas Guilbaud, Pierre Boyé, François Machuron, Pierre Ferré, François Serres, Laurent Marescaux, Sandy Courapied, Kévyn Geeraert, Aurélie Pétain, Claire Mazuy, Corinne Fournel-Fleury, Juliette Hordeaux, Dominique Tierny, Agata Marta Rybicka, Virginie Coste, Zacharie Segaoula, Bruno Gomes, Alain Duhamel, Emmanuel Bouchaert, Franck Floch

Publikováno v: Boyé, P, Floch, F, Serres, F, Segaoula, Z, Hordeaux, J, Pascal, Q, Coste, V, Courapied, S, Bouchaert, E, Rybicka, A, Mazuy, C, Marescaux, L, Geeraert, K, Fournel-Fleury, C, Duhamel, A, Machuron, F, Ferré, P, Pétain, A, Guilbaud, N, Tierny, D & Gomes, B 2020, ' Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma ', Oncotarget, vol. 11, no. 7, pp. 671-686 . https://doi.org/10.18632/oncotarget.27461
Oncotarget
Oncotarget, 2020, Oncotarget, 11, pp.671-686. ⟨10.18632/oncotarget.27461⟩

International audience; Purpose: F14512 is an epipodophyllotoxin derivative from etoposide, combined with a spermine moiety introduced as a cell delivery vector. The objective of this study was to compare the safety and antitumor activity of F14512 a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::850744eef564c2e4927bae2bf11c68b1
https://www.pure.ed.ac.uk/ws/files/138529322/27461_1049601_1_PB.pdf